Medications Modulating the Acid Sphingomyelinase/Ceramide System and 28-Day Mortality among Patients with SARS-CoV-2: An Observational Study DOI Creative Commons
Nicolas Hoertel, Katayoun Rezaei, Marina Sánchez‐Rico

et al.

Pharmaceuticals, Journal Year: 2023, Volume and Issue: 16(8), P. 1107 - 1107

Published: Aug. 4, 2023

Prior evidence indicates the potential central role of acid sphingomyelinase (ASM)/ceramide system in infection cells with SARS-CoV-2. We conducted a multicenter retrospective observational study including 72,105 adult patients laboratory-confirmed SARS-CoV-2 who were admitted to 36 AP-HP (Assistance Publique-Hôpitaux de Paris) hospitals from 2 May 2020 31 August 2022. examined association between ongoing use medications functionally inhibiting (FIASMA), which reduces vitro, upon hospital admission 28-day all-cause mortality 1:1 ratio matched analytic sample based on clinical characteristics, disease severity and other (N = 9714). The univariate Cox regression model showed that FIASMA medication at was associated significantly lower risks (HR 0.80; 95% CI 0.72-0.88; p < 0.001). In this study, substantially reduced among hospitalized COVID-19. These findings support continuation these during treatment infections. Randomized trials (RCTs) are needed confirm results, starting molecules greatest effect size e.g., fluoxetine, escitalopram, amlodipine.

Language: Английский

Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19：a meta-analysis DOI Creative Commons
Wen Wen, Chen Chen,

Jiake Tang

et al.

Annals of Medicine, Journal Year: 2022, Volume and Issue: 54(1), P. 516 - 523

Published: Feb. 4, 2022

The coronavirus disease (COVID-19) epidemic has not been completely controlled. Although great achievements have made in COVID-19 research and many antiviral drugs shown good therapeutic effects against COVID-19, a simple oral drug for yet developed. We conducted meta-analysis to investigate the improvement mortality or hospitalization rates adverse events among patients with three new antivirals (including molnupiravir, fluvoxamine Paxlovid).We searched scientific medical databases, such as PubMed, Web of Science, Embase Cochrane Library relevant articles screened references retrieved studies on COVID-19.A total eight were included this study. group 2440 patients, including 54 who died hospitalized. control 2348 118 overall odds ratio (OR) was 0.33 (95% confidence interval [CI], 0.22-0.49) placebo group, indicating that effective reduced by approximately 67%.This study showed novel (molnupiravir, Paxlovid) are reducing COVID-19. In addition, did increase occurrence events, thus exhibiting safety. These still being studied, available data suggest they will bring hope recovery potential be breakthrough very promising treatment COVID-19.KEY MESSAGESMany effects, there is no patients.Meta-analysis evaluate patients.We focussed Coronavirus agents provide guidance roll-out antivirals.

Language: Английский

Citations

401
Mechanisms of action of fluvoxamine for COVID-19: a historical review DOI Open Access
Yaeko Hashimoto, Takuji Suzuki, Kenji Hashimoto

et al.

Molecular Psychiatry, Journal Year: 2022, Volume and Issue: 27(4), P. 1898 - 1907

Published: Jan. 7, 2022

Language: Английский

Citations

109
Evolution of SARS-CoV-2 Variants: Implications on Immune Escape, Vaccination, Therapeutic and Diagnostic Strategies DOI Creative Commons
Nur Zawanah Zabidi, Hern Liang Liew, Isra Ahmad Farouk

et al.

Viruses, Journal Year: 2023, Volume and Issue: 15(4), P. 944 - 944

Published: April 10, 2023

The COVID-19 pandemic caused by SARS-CoV-2 is associated with a lower fatality rate than its SARS and MERS counterparts. However, the rapid evolution of has given rise to multiple variants varying pathogenicity transmissibility, such as Delta Omicron variants. Individuals advanced age or underlying comorbidities, including hypertension, diabetes cardiovascular diseases, are at higher risk increased disease severity. Hence, this resulted in an urgent need for development better therapeutic preventive approaches. This review describes origin human coronaviruses, particularly well sub-variants. Risk factors that contribute severity implications co-infections also considered. In addition, various antiviral strategies against COVID-19, novel repurposed drugs targeting viral host proteins, immunotherapeutic strategies, discussed. We critically evaluate current emerging vaccines their efficacy, immune evasion new impact on diagnostic testing examined. Collectively, global research public health authorities, along all sectors society, prepare upcoming future coronavirus outbreaks.

Language: Английский

Citations

70
Safety and efficacy of fluvoxamine in COVID‐19 ICU patients: An open label, prospective cohort trial with matched controls DOI Open Access

Martina Čalušić,

Robert Marčec,

Lea Luksa

et al.

British Journal of Clinical Pharmacology, Journal Year: 2021, Volume and Issue: 88(5), P. 2065 - 2073

Published: Nov. 1, 2021

Aims Fluvoxamine, a selective serotonin reuptake inhibitor (SSRI) and sigma‐1 receptor agonist, has so far shown promise in the prevention of COVID‐19 progression as an early treatment option three trials. The aim this study was to evaluate safety efficacy fluvoxamine patients if administered later course disease. Methods designed open‐label, prospective cohort trial with matched controls. In April May 2021, 51 ICU hospitalised University Hospital Dubrava Centre Zagreb, Croatia, were treated 100 mg times daily for 15 days addition standard therapy they prospectively age, gender, vaccination against COVID‐19, disease severity comorbidities Results No statistically significant differences between groups observed regarding number on ventilator support, duration or total hospital stay. However, overall mortality lower group, 58.8% ( n = 30/51), than control 76.5% 39/51), HR 0.58, 95% CI (0.36–0.94, P .027). Conclusion Fluvoxamine could have positive impact patient survival. Further studies effects are urgently required.

Language: Английский

Citations

73
Efficacy and safety of selective serotonin reuptake inhibitors in COVID-19 management: a systematic review and meta-analysis DOI Creative Commons
Jiawen Deng, Daniel Rayner, Harikrishnaa Ba Ramaraju

et al.

Clinical Microbiology and Infection, Journal Year: 2023, Volume and Issue: 29(5), P. 578 - 586

Published: Jan. 16, 2023

Language: Английский

Citations

23
Sigma-1 Receptor Specific Biological Functions, Protective Role, and Therapeutic Potential in Cardiovascular Diseases DOI
Ahmed Al‐Maamari,

Marwa Sultan,

Tao Zhang

et al.

Cardiovascular Toxicology, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 12, 2025

Language: Английский

Citations

1
Association between FIASMA psychotropic medications and reduced risk of intubation or death in individuals with psychiatric disorders hospitalized for severe COVID-19: an observational multicenter study DOI Creative Commons
Nicolas Hoertel, Marina Sánchez‐Rico, Erich Gulbins

et al.

Translational Psychiatry, Journal Year: 2022, Volume and Issue: 12(1)

Published: March 3, 2022

Abstract The acid sphingomyelinase (ASM)/ceramide system may provide a useful framework for better understanding SARS-CoV-2 infection and the repurposing of psychotropic medications functionally inhibiting sphingomyelinase/ceramide (named FIASMA medications) against COVID-19. We examined potential usefulness in patients with psychiatric disorders hospitalized severe COVID-19, an observational multicenter study conducted at Greater Paris University hospitals. Of 545 adult inpatients, 164 (30.1%) received medication upon hospital admission compared composite endpoint intubation or death between who baseline those did not time-to-event analyses adjusted sociodemographic characteristics, other medical comorbidity, medications. use was significantly associated reduced risk both crude (HR = 0.42; 95%CI 0.31–0.57; p < 0.01) primary inverse probability weighting (IPW) 0.50; 0.37–0.67; analyses. This association specific to one class medication. Patients taking antidepressant had non-FIASMA 0.57; 0.38–0.86; IPW 0.37–0.87; These associations remained significant multiple sensitivity Our results show importance ASM/ceramide COVID-19 support continuation these need large- scale clinical trials evaluating medications, particularly antidepressants,

Language: Английский

Citations

31
Sigma-1 Receptor Signaling: In Search of New Therapeutic Alternatives for Cardiovascular and Renal Diseases DOI Open Access
Francisco Javier Munguía-Galaviz, Alejandra Guillermina Miranda‐Díaz,

Miguel Alejandro Cardenas-Sosa

et al.

International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(3), P. 1997 - 1997

Published: Jan. 19, 2023

Cardiovascular and renal diseases are among the leading causes of death worldwide, regardless current efforts, there is a demanding need for therapeutic alternatives to reduce their progression advanced stages. The stress caused by leads activation protective mechanisms in cell, including chaperone proteins. Sigma-1 receptor (Sig-1R) ligand-operated protein that modulates signal transduction during cellular processes. Sig-1R interacts with various ligands proteins elicit distinct responses, thus, making it potential target pharmacological modulation. Furthermore, activate signaling pathways promote cardioprotection, ameliorate ischemic injury, drive myofibroblast fibrosis. role has also made point interest developing clinical trials pain, neurodegeneration, stroke, depression patients heart failure, COVID-19. preclinical models have significantly beneficial effects associated improved cardiac function, ventricular remodeling, hypertrophy reduction, and, kidney, reduced damage. These basic discoveries could inform failure (HF), myocardial hypertrophy, acute kidney injury (AKI), chronic disease (CKD). Here, we review evidence modulation support use agonists antagonists these diseases.

Language: Английский

Citations

22
Overview of the potential use of fluvoxamine for COVID-19 and long COVID DOI Creative Commons
Kenji Hashimoto

Discover Mental Health, Journal Year: 2023, Volume and Issue: 3(1)

Published: March 21, 2023

Abstract Coronavirus disease 2019 (COVID-19) has presented a serious worldwide threat to public health since its emergence in late 2019. From safety point of view, drug repurposing received particular attention. Several clinical studies have demonstrated that the use fluvoxamine, selective serotonin reuptake inhibitor with potent sigma-1 receptor agonism, early-stage infection might be associated prevention deterioration individuals SARS-CoV-2 infection, although several reports shown low dose fluvoxamine may ineffective. There is increasing evidence can cross blood–brain barrier, resulting number psychiatric and neurologic symptoms COVID-19 survivors. Importantly, about half survivors experience variety long-term sequelae, including symptoms, known as long COVID. In this priority review, author presents an overview potential treatment

Language: Английский

Citations

20
The effect of antidepressants on the severity of COVID-19 in hospitalized patients: A systematic review and meta-analysis DOI Creative Commons
Hosein Nakhaee, Moein Zangiabadian,

R. Bayati

et al.

PLoS ONE, Journal Year: 2022, Volume and Issue: 17(10), P. e0267423 - e0267423

Published: Oct. 6, 2022

Introduction Clinical Depression and the subsequent low immunity is a comorbidity that can act as risk factor for severity of COVID-19 cases. Antidepressants such Selective serotonin reuptake inhibitor Serotonin-norepinephrine inhibitors are associated with immune-modulatory effects, which dismiss inflammatory responses reduce lung tissue damage. The current systematic review meta-analysis aims to evaluate effect antidepressant drugs on prognosis in hospitalized patients. Methods A search was carried out PubMed/Medline, EMBASE, Scopus up June 14, 2022. following keywords were used: "COVID-19", "SARS-CoV-2", "2019-nCoV", "SSRI", "SNRI", “TCA”, “MAOI”, “Antidepressant”. fixed or random-effect model assessed pooled ratio (RR) 95% CI. We considered P < 0.05 statistically significant publication bias. Data analyzed by Comprehensive Meta-Analysis software, Version 2.0 (Biostat, Englewood, NJ). Results Fourteen studies included our review. Five them experimental 2350, nine observational 290,950 participants. Eight fourteen articles revealed antidepressants reducing COVID-19. drugs, including Fluvoxamine, Escitalopram, Fluoxetine, Paroxetine, among medications Venlafaxine, reasonably reduced intubation death. showed no effect, only one high bias article negative Covid-19. clinical trials fluvoxamine could significantly decrease outcomes (RR: 0.763; CI: 0.602–0.966, I2: 0.0) Findings Most evidence supports use medications, mainly may improve outcome patients SARS-CoV-2. Some contradictory findings regarding effects Further should be conducted clarify

Language: Английский

Citations

26